AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) datopotamab deruxtecan, or Dato-DXd, reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors in a trial, the companies announced. Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan demonstrated a statistically significant improvement for the primary endpoint of progression-free survival, or PFS, compared to docetaxel, the current standard of care, in patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, treated with at least one prior line of therapy, the companies stated. These data will be shared today in the second of two late-breaking presentations for datopotamab deruxtecan in a Presidential Symposium at the European Society for Medical Oncology, or ESMO, 2023 Congress in Madrid, Spain.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo’s Enhertu approved in EU for certain NSCLC
- Updated results from BEGONIA Phase Ib/II trial presented at ESMO
- Results from primary analysis of the DUO-E Phase III trial presented at ESMO
- AstraZeneca’s TAGRISSO plus chemotherapy results presented at ESMO
- AstraZeneca reports ‘positive’ results from interim analysis of MATTERHORN trial
